SCHEMBL3964516

SCHEMBL3964516

CC(C)c1ccc(C2(Cc3cccc(Cl)c3)C(=O)Nc3cc(Cl)ccc32)cc1

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 11/20 0.67
TP53 P04637 10/20 0.67
TOP2A P11388 1/20 0.41
PGR P06401 2/20 0.39
MAOB P27338 1/20 0.39
PNMT P11086 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
GHSR Q92847 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3970206 0.85 MDM2 (0.66) MDM2TP53PGRMAOBPDE4A
SCHEMBL3969840 0.84 MDM2 (0.70) MDM2TP53PGRMAOBPDE4A
SCHEMBL3968966 0.84 MDM2 (0.70) MDM2TP53PGRMAOBPDE4A
SCHEMBL3967825 0.82 MDM2 (0.60) MDM2TP53PGRPDE4APDE4B
SCHEMBL3969641 0.81 MDM2 (0.86) MDM2TP53TOP2APGRMAOB
SCHEMBL3968099 0.80 MDM2 (1.00) MDM2TP53PGRMAOBPDE4A
SCHEMBL3968096 0.80 MDM2 (1.00) MDM2TP53PGRMAOBPDE4A
SCHEMBL3969747 0.80 MDM2 (0.70) MDM2TP53PGRMAOBPDE4A
SCHEMBL3967431 0.79 MDM2 (0.66) MDM2TP53PGRMAOBPDE4A
SCHEMBL3964524 0.78 MDM2 (0.62) MDM2TP53PGRMAOBGHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US claimed
JP-2008543917-A 2008-12-04 JP claimed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP claimed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO claimed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US claimed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293319-A1 Oxindole derivatives CCNI, OGFR, MKI67 MDM2 759/4885TP53 96/4885TOP2A 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.